

Alberto Lle

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3625475/alberto-lleo-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

261
papers

12,958
citations

50
h-index

110
g-index

306
ext. papers

17,314
ext. citations

7
avg, IF

5.46
L-index

#	Paper	IF	Citations
261	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.. <i>JAMA Neurology</i> , 2022 ,	17.2	9
260	The A β -42/A β -40 ratio in CSF is more strongly associated to tau markers and clinical progression than A β -42 alone.. <i>Alzheimer's Research and Therapy</i> , 2022 , 14, 20	9	0
259	Cortical microstructure in primary progressive aphasia: a multicenter study.. <i>Alzheimer's Research and Therapy</i> , 2022 , 14, 27	9	0
258	Neuropsychological deficits in patients with cognitive complaints after COVID-19.. <i>Brain and Behavior</i> , 2022 , e2508	3.4	8
257	Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles.. <i>Journal of Neural Transmission</i> , 2022 , 129, 231	4.3	0
256	Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease.. <i>Molecular Neurodegeneration</i> , 2022 , 17, 27	19	1
255	Genome-Wide Association Study of Alzheimer's Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery Dataset.. <i>Frontiers in Aging Neuroscience</i> , 2022 , 14, 840651	5.3	0
254	Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration.. <i>Molecular Neurodegeneration</i> , 2022 , 17, 29	19	1
253	New insights into the genetic etiology of Alzheimer's disease and related dementias.. <i>Nature Genetics</i> , 2022 ,	36.3	27
252	Diagnostic Accuracy of Magnetic Resonance Imaging Measures of Brain Atrophy Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Degeneration.. <i>JAMA Network Open</i> , 2022 , 5, e229588	10.4	1
251	Association of Alzheimer Disease With Life Expectancy in People With Down Syndrome. <i>JAMA Network Open</i> , 2022 , 5, e2212910	10.4	2
250	Leveraging large multi-center cohorts of Alzheimer disease endophenotypes to understand the role of Klotho heterozygosity on disease risk. <i>PLoS ONE</i> , 2022 , 17, e0267298	3.7	1
249	Pathophysiological Underpinnings of Extra-Motor Neurodegeneration in Amyotrophic Lateral Sclerosis: New Insights From Biomarker Studies.. <i>Frontiers in Neurology</i> , 2021 , 12, 750543	4.1	0
248	Sex differences in the behavioral variant of frontotemporal dementia: A new window to executive and behavioral reserve. <i>Alzheimer's and Dementia</i> , 2021 , 17,	1.2	3
247	Plasma Tau and Neurofilament Light in Frontotemporal Lobar Degeneration and Alzheimer Disease. <i>Neurology</i> , 2021 , 96, e671-e683	6.5	21
246	Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021 ,	5.9	2
245	Replication study of plasma proteins relating to Alzheimer's pathology. <i>Alzheimer's and Dementia</i> , 2021 , 17, 1452-1464	1.2	4

244	Diagnostic Utility of Measuring Cerebral Atrophy in the Behavioral Variant of Frontotemporal Dementia and Association With Clinical Deterioration. <i>JAMA Network Open</i> , 2021 , 4, e211290	10.4	3
243	CSF sTREM2 is elevated in a subset in GRN-related frontotemporal dementia. <i>Neurobiology of Aging</i> , 2021 , 103, 158.e1-158.e5	5.6	2
242	AMYQ: An index to standardize quantitative amyloid load across PET tracers. <i>Alzheimer's and Dementia</i> , 2021 , 17, 1499-1508	1.2	4
241	Different Inflammatory Signatures in Alzheimer's Disease and Frontotemporal Dementia Cerebrospinal Fluid. <i>Journal of Alzheimer's Disease</i> , 2021 , 81, 629-640	4.3	1
240	State-of-the-art of lumbar puncture and its place in the journey of patients with Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021 ,	1.2	6
239	TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels. <i>Alzheimer's and Dementia</i> , 2021 , 17, 1628-1640	1.2	4
238	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. <i>Nature Communications</i> , 2021 , 12, 3417	17.4	23
237	Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021 , 92, 1206-1214	5.5	10
236	VAMP-2 is a surrogate cerebrospinal fluid marker of Alzheimer-related cognitive impairment in adults with Down syndrome. <i>Alzheimer's Research and Therapy</i> , 2021 , 13, 119	9	1
235	A multicentre validation study of the diagnostic value of plasma neurofilament light. <i>Nature Communications</i> , 2021 , 12, 3400	17.4	51
234	Plasma Proteomic Biomarkers Relating to Alzheimer's Disease: A Meta-Analysis Based on Our Own Studies. <i>Frontiers in Aging Neuroscience</i> , 2021 , 13, 712545	5.3	3
233	Genetic variation in APOE, GRN, and TP53 are phenotype modifiers in frontotemporal dementia. <i>Neurobiology of Aging</i> , 2021 , 99, 99.e15-99.e22	5.6	3
232	Biphasic cortical macro- and microstructural changes in autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021 , 17, 618-628	1.2	11
231	Nerve growth factor (NGF) pathway biomarkers in Down syndrome prior to and after the onset of clinical Alzheimer's disease: A paired CSF and plasma study. <i>Alzheimer's and Dementia</i> , 2021 , 17, 605-617 ^{1.2}	1.2	8
230	White Matter Hyperintensities Are No Major Confounder for Alzheimer's Disease Cerebrospinal Fluid Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2021 , 79, 163-175	4.3	2
229	Biomarker counseling, disclosure of diagnosis and follow-up in patients with mild cognitive impairment: A European Alzheimer's disease consortium survey. <i>International Journal of Geriatric Psychiatry</i> , 2021 , 36, 324-333	3.9	9
228	Multilingualism in semantic dementia: language-dependent lexical retrieval from degraded conceptual representations. <i>Aphasiology</i> , 2021 , 35, 240-266	1.6	3
227	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. <i>Nature Genetics</i> , 2021 , 53, 294-303	36.3	31

226	Sex differences in the behavioral variant of frontotemporal dementia: A new window to executive and behavioral reserve. <i>Alzheimer's and Dementia</i> , 2021 , 17, 1329-1341	1.2	10
225	Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndrome. <i>Nature Communications</i> , 2021 , 12, 4304	17.4	11
224	CSF Proteomic Alzheimer's Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals. <i>Proteomes</i> , 2021 , 9,	4.6	2
223	Association of Apolipoprotein E e4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome. <i>JAMA Neurology</i> , 2021 , 78, 937-947	17.2	11
222	Metabolite Signature of Alzheimer's Disease in Adults with Down Syndrome. <i>Annals of Neurology</i> , 2021 , 90, 407-416	9.4	3
221	Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study. <i>Lancet Neurology</i> , 2021 , 20, 605-614	24.1	9
220	Dense core vesicle markers in CSF and cortical tissues of patients with Alzheimer's disease. <i>Translational Neurodegeneration</i> , 2021 , 10, 37	10.3	0
219	Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer's disease, but not in cerebral amyloid angiopathy. <i>Alzheimer's Research and Therapy</i> , 2021 , 13, 160	9	0
218	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview.. <i>Alzheimer's and Dementia</i> , 2021 ,	1.2	3
217	Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia. <i>Translational Neurodegeneration</i> , 2021 , 10, 50	10.3	1
216	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. <i>Alzheimer's and Dementia</i> , 2021 , 17,	1.2	1
215	Transcriptome-wide characterization of the frontal cortex in FTLD.. <i>Alzheimer's and Dementia</i> , 2021 , 17 Suppl 3, e049569	1.2	
214	Exome sequencing identifies rare damaging variants in the ATB8B4 and ABCA1 genes as novel risk factors for Alzheimer's disease.. <i>Alzheimer's and Dementia</i> , 2021 , 17 Suppl 3, e055982	1.2	0
213	Identification of plasma proteome signatures associated with ATN framework using SOMAscan. <i>Alzheimer's and Dementia</i> , 2020 , 16, e036954	1.2	1
212	AmyQ: An index to accurately measure cerebral amyloid load. <i>Alzheimer's and Dementia</i> , 2020 , 16, e039735		
211	Oligodendroglial alterations in FTD caused by C9orf72 expansion. <i>Alzheimer's and Dementia</i> , 2020 , 16, e040196	1.2	
210	Cerebrospinal fluid neuroinflammatory biomarkers along the Alzheimer disease continuum in Down syndrome. <i>Alzheimer's and Dementia</i> , 2020 , 16, e041255	1.2	
209	Characteristics and prognosis of patients with mild cognitive impairment by cerebrospinal fluid biomarker profiles. <i>Alzheimer's and Dementia</i> , 2020 , 16, e041500	1.2	

208	Quantifying the synaptic vesicle-associated protein, VAMP2, to verify changes in cerebrospinal fluid in preclinical stages of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020 , 16, e042717	1.2	
207	Transcriptome characterization of the motor cortex suggests microglial-related key events due to TDP-43 aberrant inclusions. <i>Alzheimer's and Dementia</i> , 2020 , 16, e042953	1.2	
206	1H-MRS signature in Alzheimer disease in Down syndrome. <i>Alzheimer's and Dementia</i> , 2020 , 16, e043346	1.2	
205	Domiciliary Alzheimer visiting in Down syndrome pilot project: Preliminary results. <i>Alzheimer's and Dementia</i> , 2020 , 16, e043491	1.2	
204	Longitudinal plasma levels of neurofilament light in Down syndrome: A multicenter study. <i>Alzheimer's and Dementia</i> , 2020 , 16, e044772	1.2	
203	Which pre-analytical confounder matters the most in the comparison of two cohorts? Tubes and storage fill volume put to the test. <i>Alzheimer's and Dementia</i> , 2020 , 16, e045060	1.2	
202	VAMP2 is a cerebrospinal fluid marker of selective hippocampal synapse loss and episodic memory performance in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020 , 16, e045268	1.2	
201	International initiative for harmonization of cerebrospinal fluid diagnostic comments in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020 , 16, e047209	1.2	1
200	Blood-based detection of early-stage Alzheimer using multiomics and machine learning. <i>Alzheimer's and Dementia</i> , 2020 , 16, e047334	1.2	
199	Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort. <i>Journal of Alzheimer's Disease</i> , 2020 , 74, 213-225	4.3	10
198	APOE ϵ genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020 , 12, 65	9	13
197	Annexin A5 prevents amyloid-induced toxicity in choroid plexus: implication for Alzheimer's disease. <i>Scientific Reports</i> , 2020 , 10, 9391	4.9	4
196	Active bilingualism delays the onset of mild cognitive impairment. <i>Neuropsychologia</i> , 2020 , 146, 107528	3.2	11
195	The Added Value of Tau-PET in the Assessment of Progressive Supranuclear Palsy. <i>Clinical Nuclear Medicine</i> , 2020 , 45, e239-e240	1.7	1
194	Downregulation of miR-335-5P in Amyotrophic Lateral Sclerosis Can Contribute to Neuronal Mitochondrial Dysfunction and Apoptosis. <i>Scientific Reports</i> , 2020 , 10, 4308	4.9	13
193	Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. <i>Lancet, The</i> , 2020 , 395, 1988-1997	4.0	74
192	Increased plasma neurofilament light chain levels in patients with type-1 diabetes with impaired awareness of hypoglycemia. <i>BMJ Open Diabetes Research and Care</i> , 2020 , 8,	4.5	3
191	CCL23: A Chemokine Associated with Progression from Mild Cognitive Impairment to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020 , 73, 1585-1595	4.3	10

190	Disease-Specific Changes in Reelin Protein and mRNA in Neurodegenerative Diseases. <i>Cells</i> , 2020 , 9,	7.9	1
189	Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics. <i>Brain</i> , 2020 , 143, 3776-3792	11.2	16
188	Detection of amyloid beta peptides in body fluids for the diagnosis of alzheimer's disease: Where do we stand?. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2020 , 57, 99-113	9.4	13
187	Role for ATXN1, ATXN2, and HTT intermediate repeats in frontotemporal dementia and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2020 , 87, 139.e1-139.e7	5.6	13
186	Cerebrospinal fluid A beta 1-40 peptides increase in Alzheimer's disease and are highly correlated with phospho-tau in control individuals. <i>Alzheimer's Research and Therapy</i> , 2020 , 12, 123	9	10
185	Motor cortex transcriptome reveals microglial key events in amyotrophic lateral sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020 , 7,	9.1	21
184	Genome-wide association study of Alzheimer's disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset. <i>Translational Psychiatry</i> , 2020 , 10, 403	8.6	10
183	Obesity impacts brain metabolism and structure independently of amyloid and tau pathology in healthy elderly. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020 , 12, e12052 ²	5.2	3
182	Cortical microstructure in the amyotrophic lateral sclerosis-frontotemporal dementia continuum. <i>Neurology</i> , 2020 , 95, e2565-e2576	6.5	10
181	Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology. <i>Journal of Alzheimer's Disease</i> , 2020 , 77, 1353-1368	4.3	4
180	Evaluation of biochemical and hematological parameters in adults with Down syndrome. <i>Scientific Reports</i> , 2020 , 10, 13755	4.9	0
179	Cerebrospinal fluid profile of NPTX2 supports role of Alzheimer's disease-related inhibitory circuit dysfunction in adults with Down syndrome. <i>Molecular Neurodegeneration</i> , 2020 , 15, 46	19	10
178	Cortical microstructural correlates of astrocytosis in autosomal-dominant Alzheimer disease. <i>Neurology</i> , 2020 , 94, e2026-e2036	6.5	17
177	Serum neurofilament light chain predicts long-term prognosis in Guillain-Barré syndrome patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020 ,	5.5	12
176	Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse. <i>Annals of Clinical and Translational Neurology</i> , 2019 , 6, 1815-1824	5.3	46
175	Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. <i>Alzheimer's and Dementia</i> , 2019 , 15, 1478-1488	1.2	22
174	Early detection of subtle motor dysfunction in cognitively normal subjects with amyloid- β positivity. <i>Cortex</i> , 2019 , 121, 117-124	3.8	3
173	Has the time arrived for cerebrospinal fluid biomarkers in psychiatric disorders?. <i>Clinica Chimica Acta</i> , 2019 , 491, 81-84	6.2	7

172	Different pattern of CSF glial markers between dementia with Lewy bodies and Alzheimer's disease. <i>Scientific Reports</i> , 2019 , 9, 7803	4.9	16
171	Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort. <i>Alzheimer's and Dementia</i> , 2019 , 15, 817-827	1.2	26
170	GBA and APOE ϵ associate with sporadic dementia with Lewy bodies in European genome wide association study. <i>Scientific Reports</i> , 2019 , 9, 7013	4.9	24
169	Inflammatory biomarkers in Alzheimer's disease plasma. <i>Alzheimer's and Dementia</i> , 2019 , 15, 776-787	1.2	74
168	Cortical microstructure in the behavioural variant of frontotemporal dementia: looking beyond atrophy. <i>Brain</i> , 2019 , 142, 1121-1133	11.2	32
167	Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019 , 11, 26	9	43
166	Nanoscale structure of amyloid- β plaques in Alzheimer's disease. <i>Scientific Reports</i> , 2019 , 9, 5181	4.9	28
165	Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum. <i>Alzheimer's and Dementia</i> , 2019 , 15, 644-654	1.2	57
164	Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study. <i>Alzheimer's and Dementia</i> , 2019 , 15, 742-753	1.2	50
163	Clinical and video-polysomnographic analysis of rapid eye movement sleep behavior disorder and other sleep disturbances in dementia with Lewy bodies. <i>Sleep</i> , 2019 , 42,	1.1	13
162	Heritability and genetic variance of dementia with Lewy bodies. <i>Neurobiology of Disease</i> , 2019 , 127, 492-501	5.1	15
161	Cerebrospinal fluid mitochondrial DNA levels in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 1535-1538	5	3
160	The gene cluster is a key modulator of soluble TREM2 and Alzheimer's disease risk. <i>Science Translational Medicine</i> , 2019 , 11,	17.5	77
159	Elevated levels of Secreted-Frizzled-Related-Protein 1 contribute to Alzheimer's disease pathogenesis. <i>Nature Neuroscience</i> , 2019 , 22, 1258-1268	25.5	28
158	Down syndrome, Alzheimer disease, and cerebral amyloid angiopathy: The complex triangle of brain amyloidosis. <i>Developmental Neurobiology</i> , 2019 , 79, 716-737	3.2	16
157	Trisomy 21 activates the kynurenine pathway via increased dosage of interferon receptors. <i>Nature Communications</i> , 2019 , 10, 4766	17.4	38
156	The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: A data set for biomarker discovery and validation in neurodegenerative disorders. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019 , 5, 597-609	6	26
155	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A β tau, immunity and lipid processing. <i>Nature Genetics</i> , 2019 , 51, 414-430	36.3	917

154	P4-525: ASSOCIATION OF CSF TAU WITH HYPERPLASTICITY IN ALZHEIMER'S DISEASE 2019 , 15, P1515-P1516		
153	IC-P-148: THE CORTICAL MICROSTRUCTURAL SIGNATURE OF ALZHEIMER'S DISEASE 2019 , 15, P119-P120		
152	O2-09-01: THE NATURAL HISTORY OF ALZHEIMER'S DISEASE IN DOWN SYNDROME 2019 , 15, P558-P560		
151	A metabolite-based machine learning approach to diagnose Alzheimer-type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019 , 5, 933-938	6	29
150	APP-derived peptides reflect neurodegeneration in frontotemporal dementia. <i>Annals of Clinical and Translational Neurology</i> , 2019 , 6, 2518-2530	5.3	10
149	Decreased circulating ErbB4 ectodomain fragments as a read-out of impaired signaling function in amyotrophic lateral sclerosis. <i>Neurobiology of Disease</i> , 2019 , 124, 428-438	7.5	7
148	HTT gene intermediate alleles in neurodegeneration: evidence for association with Alzheimer's disease. <i>Neurobiology of Aging</i> , 2019 , 76, 215.e9-215.e14	5.6	13
147	Impact of CSF storage volume on the analysis of Alzheimer's disease biomarkers on an automated platform. <i>Clinica Chimica Acta</i> , 2019 , 490, 98-101	6.2	11
146	Changes in Synaptic Proteins Precede Neurodegeneration Markers in Preclinical Alzheimer's Disease Cerebrospinal Fluid. <i>Molecular and Cellular Proteomics</i> , 2019 , 18, 546-560	7.6	66
145	A comprehensive screening of copy number variability in dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2019 , 75, 223.e1-223.e10	5.6	10
144	Elevated YKL-40 and low sAPP β /YKL-40 ratio in antemortem cerebrospinal fluid of patients with pathologically confirmed FTLD. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019 , 90, 180-186	5.5	15
143	Challenges associated with biomarker-based classification systems for Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018 , 10, 346-357	5.2	25
142	Cerebral changes and disrupted gray matter cortical networks in asymptomatic older adults at risk for Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018 , 64, 58-67	5.6	7
141	White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation. <i>Alzheimer's Research and Therapy</i> , 2018 , 10, 30	9	29
140	Prevalence of the apolipoprotein E ϵ 4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018 , 14, 913-924	1.2	36
139	Rare nonsynonymous variants in SORT1 are associated with increased risk for frontotemporal dementia. <i>Neurobiology of Aging</i> , 2018 , 66, 181.e3-181.e10	5.6	12
138	A 2-Step Cerebrospinal Algorithm for the Selection of Frontotemporal Lobar Degeneration Subtypes. <i>JAMA Neurology</i> , 2018 , 75, 738-745	17.2	32
137	Cortical microstructural changes along the Alzheimer's disease continuum. <i>Alzheimer's and Dementia</i> , 2018 , 14, 340-351	1.2	60

136	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. <i>World Journal of Biological Psychiatry</i> , 2018 , 19, 244-328	3.8	148
135	Analysis of known amyotrophic lateral sclerosis and frontotemporal dementia genes reveals a substantial genetic burden in patients manifesting both diseases not carrying the expansion mutation. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018 , 89, 162-168	5.5	36
134	The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics. <i>Alzheimer's Research and Therapy</i> , 2018 , 10, 64	9	31
133	Alzheimer's disease: An ignored condition. <i>Medicina Clínica (English Edition)</i> , 2018 , 150, 432-433	0.3	1
132	Clinical Subtypes of Dementia with Lewy Bodies Based on the Initial Clinical Presentation. <i>Journal of Alzheimer's Disease</i> , 2018 , 64, 505-513	4.3	9
131	No supportive evidence for TIA1 gene mutations in a European cohort of ALS-FTD spectrum patients. <i>Neurobiology of Aging</i> , 2018 , 69, 293.e9-293.e11	5.6	11
130	Distinct Clinical Features and Outcomes in Motor Neuron Disease Associated with Behavioural Variant Frontotemporal Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2018 , 45, 220-231	2.6	4
129	Obesity and Alzheimer's disease, does the obesity paradox really exist? A magnetic resonance imaging study. <i>Oncotarget</i> , 2018 , 9, 34691-34698	3.3	37
128	Association of Cerebral Amyloid- β Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , 2018 , 75, 84-95	14.5	94
127	Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. <i>Lancet Neurology</i> , 2018 , 17, 64-74	24.1	121
126	Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to early-onset Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018 , 10, 99-111	5.2	4
125	P3-233: PLASMA PRIMARY FATTY AMIDES ASSOCIATE TO CSF AMYLOID LEVELS AND ALZHEIMER'S DISEASE PROGRESSION IN THE EMIF-AD BIOMARKER DISCOVERY COHORT 2018 , 14, P1161-P1161		
124	P4-076: CEREBROSPINAL FLUID CORE BIOMARKERS ALLOW AN ACCURATE DIAGNOSIS OF ALZHEIMER'S DISEASE IN DOWN SYNDROME 2018 , 14, P1463-P1464		
123	Prevalence of Sleep Disorders in Adults With Down Syndrome: A Comparative Study of Self-Reported, Actigraphic, and Polysomnographic Findings. <i>Journal of Clinical Sleep Medicine</i> , 2018 , 14, 1725-1733	3.1	34
122	F1-02-04: GENOMICS AND EPIGENOMICS ANALYSES IN THE EMIF-AD MULTIMODAL BIOMARKER DISCOVERY STUDY 2018 , 14, P204-P204		
121	P2-262: A CEREBROSPINAL FLUID PANEL OF SYNAPTIC PROTEINS ACROSS THE ENTIRE ALZHEIMER'S DISEASE CONTINUUM 2018 , 14, P777-P777		
120	P3-394: CORTICAL MEAN DIFFUSIVITY MAY BE MORE SENSITIVE IN DETECTING STRUCTURAL CHANGES IN FRONTOTEMPORAL DEMENTIA THAN CORTICAL THICKNESS 2018 , 14, P1248-P1249		
119	O5-04-01: A RARE GENETIC VARIANT IN THE PLCG2 GENE IS ASSOCIATED WITH A REDUCED RISK OF ALL MAJOR TYPES OF DEMENTIA AND AN INCREASED RISK TO REACH AN EXTREMELY OLD AGE 2018 , 14, P1648-P1649		

118	P1-277: CORRELATION BETWEEN INNOTEST [®] AND THE FULLY AUTOMATED LUMIPULSE [®] G PLATFORM FOR THE ANALYSIS OF β AMYLOID 1-42 AND TOTAL TAU 2018 , 14, P388-P389		1
117	Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [F]-Flutemetamol PET Scan Result. <i>Frontiers in Aging Neuroscience</i> , 2018 , 10, 409	5.3	20
116	CSF sAPP β YKL-40, and NFL along the ALS-FTD spectrum. <i>Neurology</i> , 2018 , 91, e1619-e1628	6.5	42
115	A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. <i>Brain</i> , 2018 , 141, 2895-2907	11.2	25
114	P1-293: IDENTIFICATION OF EXOSOMAL MICRORNAS AS POTENTIAL DIAGNOSTIC BIOMARKERS FOR FRONTOTEMPORAL DEMENTIA 2018 , 14, P398-P399		
113	Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimer's Disease Cerebrospinal Fluid Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2018 , 66, 639-652	4.3	8
112	Data driven diagnostic classification in Alzheimer's disease based on different reference regions for normalization of PiB-PET images and correlation with CSF concentrations of A β species. <i>NeuroImage: Clinical</i> , 2018 , 20, 603-610	5.3	7
111	Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. <i>Lancet Neurology</i> , 2018 , 17, 860-869	24.1	105
110	A Common Variant in the MC1R Gene (p.V92M) is associated with Alzheimer's Disease Risk. <i>Journal of Alzheimer's Disease</i> , 2017 , 56, 1065-1074	4.3	1
109	Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes. <i>Journal of Alzheimer's Disease</i> , 2017 , 56, 543-555	4.3	7
108	MicroRNA Profile in Patients with Alzheimer's Disease: Analysis of miR-9-5p and miR-598 in Raw and Exosome Enriched Cerebrospinal Fluid Samples. <i>Journal of Alzheimer's Disease</i> , 2017 , 57, 483-491	4.3	90
107	Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomal-dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017 , 13, 1251-1260	1.2	38
106	Deleterious ABCA7 mutations and transcript rescue mechanisms in early onset Alzheimer's disease. <i>Acta Neuropathologica</i> , 2017 , 134, 475-487	14.3	34
105	Regional Overlap of Pathologies in Lewy Body Disorders. <i>Journal of Neuro pathology and Experimental Neurology</i> , 2017 , 76, 216-224	3.1	34
104	Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment due to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017 , 58, 909-918	4.3	17
103	C-terminal fragments of the amyloid precursor protein in cerebrospinal fluid as potential biomarkers for Alzheimer disease. <i>Scientific Reports</i> , 2017 , 7, 2477	4.9	21
102	CSF sAPP β YKL-40, and neurofilament light in frontotemporal lobar degeneration. <i>Neurology</i> , 2017 , 89, 178-188	6.5	75
101	Consensus guidelines for lumbar puncture in patients with neurological diseases. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017 , 8, 111-126	5.2	128

100	The frequency and influence of dementia risk factors in prodromal Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017 , 56, 33-40	5.6	19
99	TBK1 Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. <i>Human Mutation</i> , 2017 , 38, 297-309	4.7	66
98	Cerebrospinal fluid mitochondrial DNA in the Alzheimer's disease continuum. <i>Neurobiology of Aging</i> , 2017 , 53, 192.e1-192.e4	5.6	19
97	[O10602]: BIPHASIC MODEL IN PRECLINICAL ALZHEIMER'S DISEASE: AV45 PET, CSF TAU AND CORTICAL THICKNESS 2017 , 13, P201-P202		
96	Ante mortem cerebrospinal fluid tau levels correlate with postmortem tau pathology in frontotemporal lobar degeneration. <i>Annals of Neurology</i> , 2017 , 82, 247-258	9.4	28
95	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. <i>Nature Genetics</i> , 2017 , 49, 1373-1384	36.3	508
94	[P1066]: WEIGHT LOSS MIGHT BE A NON-COGNITIVE SIGN OF PRECLINICAL ALZHEIMER'S DISEASE 2017 , 13, P399-P400		
93	[P3074]: STRUCTURAL CORRELATES OF ALZHEIMER'S DISEASE AND AGING IN DOWN SYNDROME: AN MRI STUDY 2017 , 13, P1048-P1048		
92	The pitfalls of biomarker-based classification schemes. <i>Alzheimer's and Dementia</i> , 2017 , 13, 1072-1074	1.2	5
91	YKL-40 (Chitinase 3-like I) is expressed in a subset of astrocytes in Alzheimer's disease and other tauopathies. <i>Journal of Neuroinflammation</i> , 2017 , 14, 118	10.1	69
90	CSF microRNA Profiling in Alzheimer's Disease: a Screening and Validation Study. <i>Molecular Neurobiology</i> , 2017 , 54, 6647-6654	6.2	29
89	Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2017 , 49, 214.e13-214.e15	5.6	10
88	Longitudinal brain structural changes in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017 , 13, 499-509	1.2	38
87	[P1038]: THE SAPP/YKL-40 RATIO IN CEREBROSPINAL FLUID AS A DIAGNOSTIC MARKER IN FRONTOTEMPORAL LOBAR DEGENERATION: A PATHOLOGICAL STUDY 2017 , 13, P335-P336		
86	[P1089]: DISCOVERY, REPLICATION AND EXTENSION STUDY OF PLASMA PROTEOMIC BIOMARKERS RELATING TO BRAIN AMYLOID BURDEN (CSF A β OR AMYLOID-PET) IN THE EMIF-AD BIOMARKER DISCOVERY COHORT 2017 , 13, P361-P362		
85	[P2059]: NETWORK ANALYSIS OF THE CSF PROTEOME IDENTIFIES SYNAPTIC PROTEINS OF HIPPOCAMPAL ORIGIN AS PUTATIVE BIOMARKERS FOR AD-RELATED SYNAPSE LOSS 2017 , 13, P712-P712		
84	[O3003]: LONGITUDINAL CEREBROSPINAL FLUID BIOMARKER TRAJECTORIES ALONG THE ALZHEIMER'S DISEASE CONTINUUM: A MULTICENTRE EUROPEAN STUDY 2017 , 13, P924		2
83	Synaptic phosphorylated β -synuclein in dementia with Lewy bodies. <i>Brain</i> , 2017 , 140, 3204-3214	11.2	64

82	Weight loss in the healthy elderly might be a non-cognitive sign of preclinical Alzheimer's disease. <i>Oncotarget</i> , 2017 , 8, 104706-104716	3.3	31
81	Kidins220 Correlates with Tau in Alzheimer's Disease Brain and Cerebrospinal Fluid. <i>Journal of Alzheimer's Disease</i> , 2017 , 55, 1327-1333	4.3	4
80	Feasibility of Lumbar Puncture in the Study of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Subjects with Down Syndrome. <i>Journal of Alzheimer's Disease</i> , 2017 , 55, 1489-1496	4.3	12
79	Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study. <i>Alzheimer's and Dementia</i> , 2016 , 12, 154-163	1.2	129
78	Use of amyloid-PET to determine cutpoints for CSF markers: A multicenter study. <i>Neurology</i> , 2016 , 86, 50-8	6.5	48
77	Non-Fibrillar Oligomeric Amyloid- β within Synapses. <i>Journal of Alzheimer's Disease</i> , 2016 , 53, 787-800	4.3	43
76	S4-01-01: Cross-Sectional Studies of Plasma Proteomic Biomarkers Relating to Pet Amyloid and CSF Amyloid and Tau 2016 , 12, P321-P321		
75	Reduced Slow-Wave Sleep Is Associated with High Cerebrospinal Fluid A β 2 Levels in Cognitively Normal Elderly. <i>Sleep</i> , 2016 , 39, 2041-2048	1.1	92
74	Copy number variation analysis of the 17q21.31 region and its role in neurodegenerative diseases. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2016 , 171B, 175-80	3.5	11
73	Assessing the role of TUBA4A gene in frontotemporal degeneration. <i>Neurobiology of Aging</i> , 2016 , 38, 215.e13-215.e14	5.6	7
72	Cerebrospinal Fluid Anti-Amyloid- β Autoantibodies and Amyloid PET in Cerebral Amyloid Angiopathy-Related Inflammation. <i>Journal of Alzheimer's Disease</i> , 2016 , 50, 1-7	4.3	29
71	Progranulin Protein Levels in Cerebrospinal Fluid in Primary Neurodegenerative Dementias. <i>Journal of Alzheimer's Disease</i> , 2016 , 50, 539-46	4.3	28
70	Exome sequencing in a consanguineous family clinically diagnosed with early-onset Alzheimer's disease identifies a homozygous CTSF mutation. <i>Neurobiology of Aging</i> , 2016 , 46, 236.e1-6	5.6	19
69	sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers. <i>EMBO Molecular Medicine</i> , 2016 , 8, 466-76		256
68	P4-122: Prevalence of Vascular Risk Factors in Different Stages of Prodromal Alzheimer's Disease and Its Influence on Cognitive Decline 2016 , 12, P1059-P1061		
67	O5-02-04: DOWN ALZHEIMER BARCELONA NEUROIMAGING INITIATIVE (DABNI): A PROSPECTIVE LONGITUDINAL BIOMARKER COHORT TO STUDY ALZHEIMER'S DISEASE IN DOWN SYNDROME 2016 , 12, P380-P381		4
66	P2-424: Obesity is Associated With Increased CSF Phospho-TAU Levels and Cognitive Decline in Healthy Elderly 2016 , 12, P807-P807		
65	O5-05-02: EVALUATION OF SYNAPTIC PROTEINS AS CEREBROSPINAL FLUID STAGE BIOMARKERS FOR ALZHEIMER'S DISEASE 2016 , 12, P388-P388		

64	Pittsburgh compound B imaging and cerebrospinal fluid amyloid- β in a multicentre European memory clinic study. <i>Brain</i> , 2016 , 139, 2540-53	11.2	93
63	Cerebrospinal fluid Presenilin-1 increases at asymptomatic stage in genetically determined Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2016 , 11, 66	19	6
62	Cerebrospinal Fluid Biomarkers for Target Engagement and Efficacy in Clinical Trials for Alzheimer's and Parkinson's Diseases. <i>Frontiers of Neurology and Neuroscience</i> , 2016 , 39, 117-23	1.1	7
61	Cerebral amyloid angiopathy-related atraumatic convexal subarachnoid hemorrhage: an ARIA before the tsunami. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2015 , 35, 710-7	7.3	30
60	Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study. <i>Neurobiology of Aging</i> , 2015 , 36, 2587-96	5.6	29
59	Analysis of the CHCHD10 gene in patients with frontotemporal dementia and amyotrophic lateral sclerosis from Spain. <i>Brain</i> , 2015 , 138, e400	11.2	47
58	Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease. <i>Neurology</i> , 2015 , 85, 626-33	6.5	107
57	Genetic variability in SQSTM1 and risk of early-onset Alzheimer dementia: a European early-onset dementia consortium study. <i>Neurobiology of Aging</i> , 2015 , 36, 2005.e15-22	5.6	29
56	Relationship between cortical thickness and cerebrospinal fluid YKL-40 in predementia stages of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015 , 36, 2018-23	5.6	64
55	Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 1924-38	27.4	842
54	Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 1939-49	27.4	379
53	PLD3 in non-familial Alzheimer's disease. <i>Nature</i> , 2015 , 520, E3-5	50.4	53
52	Qualitative changes in human β -secretase underlie familial Alzheimer's disease. <i>Journal of Experimental Medicine</i> , 2015 , 212, 2003-13	16.6	104
51	Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. <i>Nature Reviews Neurology</i> , 2015 , 11, 41-55	15	116
50	The use of biomarkers for the etiologic diagnosis of MCI in Europe: an EADC survey. <i>Alzheimer's and Dementia</i> , 2015 , 11, 195-206.e1	1.2	45
49	Informants' Perception of Subjective Cognitive Decline Helps to Discriminate Preclinical Alzheimer's Disease from Normal Aging. <i>Journal of Alzheimer's Disease</i> , 2015 , 48 Suppl 1, S87-98	4.3	39
48	Early Cerebellar Hypometabolism in Patients With Frontotemporal Dementia Carrying the C9orf72 Expansion. <i>Alzheimer Disease and Associated Disorders</i> , 2015 , 29, 353-6	2.5	7
47	P1-121: Comparison of different β -amyloid isoforms in CSF to detect amyloid pathology in cognitively normal subjects and patients with dementia 2015 , 11, P387-P387		

46	O4-11-04: Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lp feasibility study 2015 , 11, P297-P297		1
45	Effect of REST on brain metabolism in the Alzheimer disease continuum. <i>Annals of Neurology</i> , 2015 , 78, 661-2	9.4	1
44	The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases. <i>Frontiers in Neurology</i> , 2015 , 6, 216	4.1	31
43	APOE-by-sex interactions on brain structure and metabolism in healthy elderly controls. <i>Oncotarget</i> , 2015 , 6, 26663-74	3.3	67
42	P1-115: Consensus guidelines to perform lumbar puncture for CSF sampling in patients with neurological conditions 2015 , 11, P384-P384		1
41	Mendelian genes for Parkinson's disease contribute to the sporadic forms of the disease. <i>Human Molecular Genetics</i> , 2015 , 24, 2023-34	5.6	20
40	Autosomal-dominant Alzheimer's disease mutations at the same codon of amyloid precursor protein differentially alter A β production. <i>Journal of Neurochemistry</i> , 2014 , 128, 330-9	6	24
39	Cerebrospinal fluid β amyloid and phospho-tau biomarker interactions affecting brain structure in preclinical Alzheimer disease. <i>Annals of Neurology</i> , 2014 , 76, 223-30	9.4	88
38	Plasma phosphorylated TDP-43 levels are elevated in patients with frontotemporal dementia carrying a C9orf72 repeat expansion or a GRN mutation. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014 , 85, 684-91	5.5	47
37	Investigation of the role of rare TREM2 variants in frontotemporal dementia subtypes. <i>Neurobiology of Aging</i> , 2014 , 35, 2657.e13-2657.e19	5.6	31
36	Frontotemporal dementia and its subtypes: a genome-wide association study. <i>Lancet Neurology</i> , 2014 , 13, 686-99	24.1	207
35	Presenilin-1 influences processing of the acetylcholinesterase membrane anchor PRiMA. <i>Neurobiology of Aging</i> , 2014 , 35, 1526-36	5.6	7
34	Posttranslational nitro-glycative modifications of albumin in Alzheimer's disease: implications in cytotoxicity and amyloid- β peptide aggregation. <i>Journal of Alzheimer's Disease</i> , 2014 , 40, 643-57	4.3	28
33	Feasibility of lumbar puncture in the study of cerebrospinal fluid biomarkers for Alzheimer's disease: a multicenter study in Spain. <i>Journal of Alzheimer's Disease</i> , 2014 , 39, 719-26	4.3	44
32	P4-267: CORE ALZHEIMER'S DISEASE CSF BIOMARKERS IN DOWN SYNDROME 2014 , 10, P882-P882		2
31	P3-230: CSF β AMYLOID AND PHOSHO-TAU INTERACTIONS ON BRAIN STRUCTURE IN PRECLINICAL AD 2014 , 10, P715-P715		
30	IC-P-217: CSF β AMYLOID AND PHOSHO-TAU INTERACTIONS ON BRAIN STRUCTURE IN PRECLINICAL AD 2014 , 10, P117-P117		
29	Relationship between β Secretase, inflammation and core cerebrospinal fluid biomarkers for Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2014 , 42, 157-67	4.3	88

28	TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. <i>Science Translational Medicine</i> , 2014 , 6, 243ra86	17.5	436
27	Assessing the role of the TREM2 p.R47H variant as a risk factor for Alzheimer's disease and frontotemporal dementia. <i>Neurobiology of Aging</i> , 2014 , 35, 444.e1-4	5.6	81
26	Acetylcholinesterase modulates presenilin-1 levels and β secretase activity. <i>Journal of Alzheimer's Disease</i> , 2014 , 41, 911-24	4.3	12
25	Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. <i>Nature Genetics</i> , 2013 , 45, 1452-8	36.3	2714
24	MAPT H1 haplotype is associated with enhanced β synuclein deposition in dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2013 , 34, 936-42	5.6	39
23	Distinct patterns of APP processing in the CNS in autosomal-dominant and sporadic Alzheimer disease. <i>Acta Neuropathologica</i> , 2013 , 125, 201-13	14.3	81
22	CSF biomarker variability in the Alzheimer's Association quality control program. <i>Alzheimer's and Dementia</i> , 2013 , 9, 251-61	1.2	289
21	Confluence of β synuclein, tau, and β amyloid pathologies in dementia with Lewy bodies. <i>Journal of Neuropathology and Experimental Neurology</i> , 2013 , 72, 1203-12	3.1	106
20	Tau enhances β synuclein aggregation and toxicity in cellular models of synucleinopathy. <i>PLoS ONE</i> , 2011 , 6, e26609	3.7	94
19	β secretase substrates and their implications for drug development in Alzheimer's disease. <i>Current Topics in Medicinal Chemistry</i> , 2011 , 11, 1513-27	3	39
18	Dementia risk in Parkinson disease: disentangling the role of MAPT haplotypes. <i>Archives of Neurology</i> , 2011 , 68, 359-64		102
17	Genetic screening of Alzheimer's disease genes in Iberian and African samples yields novel mutations in presenilins and APP. <i>Neurobiology of Aging</i> , 2010 , 31, 725-31	5.6	162
16	Clinical, neuropathologic, and biochemical profile of the amyloid precursor protein I716F mutation. <i>Journal of Neuropathology and Experimental Neurology</i> , 2010 , 69, 53-9	3.1	37
15	Mild cholesterol depletion reduces amyloid-beta production by impairing APP trafficking to the cell surface. <i>Journal of Neurochemistry</i> , 2009 , 110, 220-30	6	49
14	Early-onset familial lewy body dementia with extensive tauopathy: a clinical, genetic, and neuropathological study. <i>Journal of Neuropathology and Experimental Neurology</i> , 2009 , 68, 73-82	3.1	29
13	Homocysteine and cognitive impairment. Relation with diagnosis and neuropsychological performance. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008 , 26, 506-12	2.6	32
12	Activity of gamma-secretase on substrates other than APP. <i>Current Topics in Medicinal Chemistry</i> , 2008 , 8, 9-16	3	63
11	Current therapeutic options for Alzheimer's disease. <i>Current Genomics</i> , 2007 , 8, 550-8	2.6	42

10	Familial Alzheimer's disease presenilin 1 mutations cause alterations in the conformation of presenilin and interactions with amyloid precursor protein. <i>Journal of Neuroscience</i> , 2005 , 25, 3009-17	6.6	126
9	Low density lipoprotein receptor-related protein (LRP) interacts with presenilin 1 and is a competitive substrate of the amyloid precursor protein (APP) for gamma-secretase. <i>Journal of Biological Chemistry</i> , 2005 , 280, 27303-9	5.4	50
8	Nonsteroidal anti-inflammatory drugs lower Abeta42 and change presenilin 1 conformation. <i>Nature Medicine</i> , 2004 , 10, 1065-6	50.5	187
7	Clinical, pathological, and biochemical spectrum of Alzheimer disease associated with PS-1 mutations. <i>American Journal of Geriatric Psychiatry</i> , 2004 , 12, 146-56	6.5	60
6	Notch1 competes with the amyloid precursor protein for gamma-secretase and down-regulates presenilin-1 gene expression. <i>Journal of Biological Chemistry</i> , 2003 , 278, 47370-5	5.4	40
5	Frequency of mutations in the presenilin and amyloid precursor protein genes in early-onset Alzheimer disease in Spain. <i>Archives of Neurology</i> , 2002 , 59, 1759-63		88
4	Uncommon polymorphism in the presenilin genes in human familial Alzheimer's disease: not to be mistaken with a pathogenic mutation. <i>Neuroscience Letters</i> , 2002 , 318, 166-8	3.3	15
3	Cerebral perfusion and haemodynamics measured by SPET in symptom-free patients with transient ischaemic attack: clinical implications. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2001 , 28, 1828-35	8.8	9
2	Diagnostic value of plasma neurofilament light: A multicentre validation study		6
1	Agreement between 18F-Florbetapir PET imaging and cerebrospinal fluid A β -42, A β -40, tTau and pTau measured on the LUMIPULSE G fully automated platform		2